Navigation Links
Xencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Date:10/1/2013

ng engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, five antibodies are in clinical development internally and with partners that have been engineered with Xencor's XmAb technology. Xencor's internally-discovered programs include XmAb5871, in Phase 2a for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in preclinical development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC and Boehringer Ingelheim.


'/>"/>
SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
2. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
3. Blood Centers of America Experiences Record Growth
4. Verenium Enters Agreement To Be Acquired By BASF
5. CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
6. Independent Living Centers Play A Vital Role In Helping Students Transition Out Of High School
7. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
10. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
11. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Shire plc (LSE: SHP, ... Mathew to its Board of Directors as a Non-Executive ... Compliance & Risk Committee of the Shire Board. Both appointments ... Sara previously served as Chairman, President and Chief Executive Officer ... During her 12-year tenure at D&B, she helped drive the ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has ... Africa Biomedical Sensors Market - Growth, Trends & Forecasts ... The Middle East & Africa ... 2018 at a CAGR of 3.26% over the period ... sensors that are adaptable to the genetic formulation of ...
(Date:8/31/2015)... , Aug. 31, 2015  US-Australian drug discovery ... ) today confirmed its comprehensive scientific review has ... platforms in areas of unmet patient need. Novogen ... remaining preclinical projects prior to entering into Phase ... Acting Chief Executive Officer, Iain ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... HAYWARD, Calif., Oct. 11 Guava Technologies today,launched ... around its,main audiences: Life Scientists, Flow Cytometrists, and ... tool for cell analysis, Guava,Technologies is dedicated to ... as possible for all life scientists and clinicians ...
... Access Genetics, an Eden Prairie-,based molecular diagnostics service and ... Hoedeman as its CFO, and Elizabeth A. Skinner,as VP ... recently CFO of Edwin Watts Golf, and has previously,served ... CIO of Allied Signal,Aerospace, and corporate controller of NCR ...
... Poll: 77% Oppose Proposal to Kill Human Embryos ... Michigan Catholic,Conference President and Chief Executive Officer Sister ... the formation of the,ballot question committee "Stem Cell ... life at its most vulnerable stage, any,proposal, legislative ...
Cached Biology Technology:New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians 2Access Genetics Announces New Executive Appointments 2
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... juillet 2015 La 10e Conférence internationale ... organisée par le BGI du 22 au 25 ... en Chine. La conférence célèbre son ... 2006, l,ICG est devenue l,une des réunions annuelles ... « omiques » et c,est aussi la plus dynamique, la ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... the past several decades, evidence has shown that greater ... the development of certain common cancers and reduces neural ... health interventions that have a great impact on health. ... DNA synthesis also means that abundant availability of the ...
... who smoked, drank, didn,t exercise or didn,t eat enough fruit ... with better health habits, according to a new study from ... has been a recent emphasis on biomarkers and genes that ... person has at diagnosis play a major role in his ...
... University College London Business PLC (UCLB) and Ocera ... signing of an exclusive worldwide licensing agreement for UCL-L1V ... for the treatment of acute hepatic encephalopathy (AHE). ... reduces blood levels of ammonia, a highly toxic chemical ...
Cached Biology News:Health benefits, consequences of folic acid dependent on circumstances 2Health choices predict cancer survival, U-M study finds 2Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB 2Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB 3